Join us for a provocative program that includes interactive case discussions and a review of the data from a panel of renowned myeloma experts who will provide varied perspectives on new data, guideline changes, and expert recommendations for management of patients with multiple myeloma.
Interact with these international experts as they debate clinical questions and discuss how these challenges can affect therapeutic decisions faced by clinicians treating myeloma.
Accurately Diagnosing MM: When Should Systemic Myeloma Treatment Be Initiated?
Presented by Bruno Paiva, PhD
Individualized Approaches to Treatment Selection for Induction Therapy
Presented by S. Vincent Rajkumar, MD
Transplant, Consolidation, and Maintenance: The Role of MRD in Monitoring
Presented by Philippe Moreau, MD
Therapeutic Strategies After First Relapse Following Initial Therapy
Presented by Jesus San Miguel, MD, PhD
Current and Future Options for Therapy in Patients With Late Relapse
Presented by Brian G.M. Durie, MD
2018 Treatment Algorithm for Multiple Myeloma
Presented by S. Vincent Rajkumar, MD
1:00 PM – 1:05 PM
Welcome and Introduction
1:05 PM – 3:50 PM
Faculty Panel Discussion and Audience Questions
3:50 PM – 4:00 PM
Final Thoughts and Question and Answer Session
- Initiate treatment for appropriate patients based on current diagnosis and staging criteria for monoclonal gammopathy of undetermined significance, smoldering MM, and active MM
- Create individualized treatment strategies for patients with MM through consideration of the available clinical data as well as risk assessment, comorbidities, age/fitness, and patient preferences
- Integrate the newly approved monoclonal antibodies into existing treatment strategies for patients with MM
- Plan appropriate treatment strategies using the new-generation proteasome inhibitors for individual patients with MM
- Consider efficacy and safety evidence of immunomodulatory agents in combination with novel agents to individualize therapeutic strategies for patients with MM
- Identify ongoing trials of investigational approaches in the treatment of MM to aid referral of patients for study participation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Allison Hughes prior to the live event at email@example.com.
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower, the International Myeloma Foundation, and Clinical Care Options LLC.
This activity is supported by educational grants from Amgen, Celgene Corporation, Janssen Oncology, Karyopharm, Takeda Oncology, and The Binding Site.